Cannapharmarx, Inc. (CPMD): Operating Income
-$3.35M
Year ended 2025-12-31
-$2.89M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$3.35M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$3.63M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$1.58M | n/m | 2025-04-10, From 2023-01-01 |
| 2022-12-31 | -$5.21M | n/m | 2023-09-01, From 2022-01-01 |
| 2021-12-31 | -$2.99M | n/m | 2023-09-01, From 2021-01-01 |
| 2020-12-31 | -$14.49M | n/m | 2022-04-15, From 2020-01-01 |
| 2019-12-31 | -$15.98M | n/m | 2021-04-14, From 2019-01-01 |
| 2018-12-31 | -$954.3K | n/m | 2020-05-27, From 2018-01-01 |
| 2017-12-31 | -$6.6K | n/m | 2019-04-03, From 2017-01-01 |
| 2016-12-31 | -$1.00M | n/m | 2018-09-14, From 2016-01-01 |
| 2015-12-31 | -$11.65M | n/m | 2018-09-14, From 2015-01-01 |
| 2014-12-31 | -$3.97M | n/m | 2015-03-31, From 2014-01-01 |
| 2013-12-31 | -$80.3K | n/m | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | -$89.6K | n/m | 2014-02-06, From 2012-01-01 |
| 2011-12-31 | -$97.1K | n/m | 2013-03-28, From 2011-01-01 |
| 2010-12-31 | $585.6K | +414.9% | 2012-03-14, From 2010-01-01 |
| 2009-12-31 | $113.7K | n/a | 2011-06-30, From 2009-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$3.35M | n/m |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$59.91M | n/m |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | -$3.08M | n/m |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | -$16.22M | n/m |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | -$7.45M | n/m |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | -$72.13M | n/m |
| Longeveron Inc. (LGVN) | 2025-12-31 | -$23.29M | n/m |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | -$16.45M | n/m |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | -$7.12M | n/m |
Compare CPMD, NWBO, ATXI, NRXP side by side · Screen every company in Pharmaceutical Preparations ↗